Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Company Overview

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Key Stats

• Today's Range: $6.04 to $6.36
• 50-Day Range: $5.10 to $7.20
• 52-Week Range: $3.68 to $7.99
• Volume: 238,304 shs
• Average Volume: 228,525 shs
• Market Capitalization: $234.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Lifecore Biomedical Stock Analysis - MarketRank™

Lifecore Biomedical scored higher than 37% of companies evaluated by MarketBeat, and ranked 707th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lifecore Biomedical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lifecore Biomedical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lifecore Biomedical is -11.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lifecore Biomedical is -11.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lifecore Biomedical has a P/B Ratio of 17.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.91% of the float of Lifecore Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Lifecore Biomedical has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Lifecore Biomedical has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lifecore Biomedical does not currently pay a dividend.

Dividend Growth

Lifecore Biomedical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.91% of the float of Lifecore Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Lifecore Biomedical has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Lifecore Biomedical has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.30

News Sentiment

Lifecore Biomedical has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lifecore Biomedical this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for LFCR on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LFCR Stock Analysis - Frequently Asked Questions

How have LFCR shares performed this year?

Lifecore Biomedical's stock was trading at $7.43 on January 1st, 2025. Since then, LFCR shares have decreased by 14.7% and is now trading at $6.34.
View the best growth stocks for 2025 here.

How were Lifecore Biomedical's earnings last quarter?

Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted its earnings results on Thursday, April, 3rd. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.05. The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 315.23% and a negative net margin of 12.52%.
Read the conference call transcript.

Who are Lifecore Biomedical's major shareholders?

Top institutional shareholders of Lifecore Biomedical include Rhumbline Advisers (0.07%), MassMutual Private Wealth & Trust FSB (0.01%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs.
View institutional ownership trends.

How do I buy shares of Lifecore Biomedical?

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lifecore Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 4/03/2025
• Today: 4/16/2025
• Fiscal Year End: 5/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LFCR
• CIK: 1005286
• Web: www.lifecore.com
• Phone: (800) 454-1355
• Fax: 650-368-9818
• Employees: 690
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +26.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $12.01 million
• Net Margins: -12.52%
• Pretax Margin: -11.40%
• Return on Equity: -315.23%
• Return on Assets: -12.74%

Debt

• Debt-to-Equity Ratio: 9.21
• Current Ratio: 2.32
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $130.86 million
• Price / Sales: 1.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 17.14

Miscellaneous

• Outstanding Shares: 37,025,000
• Free Float: 26,580,000
• Market Cap: $234.74 million
• Optionable: Optionable
• Beta: 0.80